Welcome to the Dendrite Fund

Recent advancements in neuroscience are opening new frontiers in healthcare, especially in the development of novel technologies to diagnose and treat diseases such as Stroke, Dementia, Alzheimer’s, Parkinson’s, Epilepsy and Seizures, Brain Tumors, and more.

Investing in next-generation neuro innovations has the potential to positively impact millions of people worldwide who suffer from challenging neurological disorders.

Why Invest in Neuroscience?

Neuroscience is one of 10 emerging technologies poised to transform our world over the next decade.

  • Stanford Emerging Technology Review, 2023

Limited Treatment Options

Poor or limited treatments for brain diseases.

Life Extension

An aging population living longer.

Increased Funding

Greater government funding supporting the science.

Modern Advancements

A generational confluence of advances in neuroscience, hardware, devices, and AI — paving the way for movement forward.

A Growing Market Opportunity

$32 Billion

In 2021

$41 Billion

In 2030

Our Fund’s
“Secret Sauce”

World-Renowned Neuro Team with Deep Sector Experience

Globally recognized authorities, supported by an experienced venture, are uniquely positioned to identify and rigorously vet companies. This deep sector expertise, and our team’s roles as end users, help us understand the competitive landscape and identify which innovations are truly “best in class.

Early Access to Paradigm-Shifting Opportunities

We have unusual access to the most competitive investment opportunities because of our team’s credentials, relationships and experience. This gives us early access to paradigm-shifting opportunities at attractive valuations, helping to maximize returns.

Value Added Services and Support

Our team’s positions at leading neuro institutions, stroke centers and CROs give us the ability to support our capital investments with other critical support (including grant assistance, trial design, regulatory support, etc.) and provide connections to strategics to drive value creation through exit.


The end of medicine

The doctor leans forward, matching my posture: elbows on knees, fist nested in his opposite palm, like a model of a ball-socket…
Read More

Factors impacting neurosurgery residents’ operative case volume: a nationwide survey

Neurological surgery residency remains one of the most competitive and longest specialties in terms of training in medicine…

This ALS patient has a brain implant that translates his thoughts to computer commands

Staring at a computer screen, Mark focuses deeply, his arms resting by his side…
Read More

Q4 2023 Medtech Report

Medtech VC funding slowed in Q4, raking in $2.6 billion, down from $3 billion raised in Q3, according to PitchBook’s latest Emerging Tech Research…

Read More

Meet the Team

Elad Levy, MD, MBA

Neurosurgery Global Thought Leader

  • Chairman, University at Buffalo Neurosurgery 
  • Co-Director, Gates Stroke Center at Kaleida Health 
  • Immediate Past President, Congress of Neurological Surgeons 
  • >600 Peer-reviewed articles
  • ~50 US/OUS clinical trials annually

Aimee DeGaetano, RD, MPH

Neurotechnology Global Thought Leader

  • Global Head, Clinical Affairs/Commercial Strategy, Vastrax (Neuro CRO)
  • Global Industry Advisory Committee, Society of Vascular and Interventional Neurology
  • Director Neurotech Research Com., Digital Medicine Society
  • Co-Author of >100 US/OUS neurotechnology abstracts, clinical studies, articles, presentations

Laszlo Metcher, MD

Neurology Global Thought Leader

  • Medical Director of Dent Neurologic Institute (one of the world’s largest neurological institutes)
  • Chief of Neuro-Oncology, Roswell Park Cancer Institute
  • Professor of Neurology and Neuro-Oncology, University at Buffalo
  •  >100 Clinical trials and studies annually

Scott Friedman

Fund Manager

  • Co-Founder & Managing Director, Varia Ventures
  • Past Chairman & Managing Partner, Lippes Mathias LLP
    Co-Team Leader of Startup & Venture Capital Practice, Lippes Mathias
  • Active Investor (Impact Capital, Niagara Gorge Venture Partners, etc.)
  • Author of seven books and numerous articles

Andrea Vossler

Fund Manager

  • Co-Founder & Managing Director, Varia Ventures
  • Co-Team Leader of Startup & Venture Capital Practice, Lippes Mathias.
  • Angel Investor and Advisor
  • Current or Past Mentor at Columbia Technology Ventures, Founders Institute, Endeavor WNY
Bryce Klontz

Venture Partner,
Med-Tech Operator

Chris Schuler

Venture Partner,
Business Development

Eliza Shea, J.D.

Venture Partner,
General Counsel

Lisa Friedman

Venture Partner,
Strategic Initiatives

Amanda Clark

Marketing Lead

Kate Huber

Tech Lead


The information contained herein is provided for informational and discussion purposes only and is not intended to be a recommendation for any investment or other advice of any kind and shall not constitute or imply any offer to purchase, sell or hold any security or to enter into or engage in any type of transaction. Any such offers will only be made pursuant to formal offering materials containing full details regarding risks, conflicts of interest, minimum investment, fees, and expenses of the fund. Information on this page is qualified in its entirety by the fund’s private placement memorandum, subscription agreement and limited liability agreement, which should be reviewed carefully prior to making an investment decision. Please see these documents for full details regarding risks, conflicts of interest, minimum investment, fees and expenses.